Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioCryst (BCRX – Research Report) and Fate Therapeutics (FATE – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioCryst (BCRX)
In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on BioCryst, with a price target of $30.00. The company’s shares closed last Thursday at $7.75.
According to TipRanks.com, Ku is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $21.50 average price target, which is a 162.4% upside from current levels. In a report issued on February 18, Evercore ISI also resumed coverage with a Buy rating on the stock with a $17.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Fate Therapeutics (FATE)
TD Cowen analyst Tara Bancroft maintained a Hold rating on Fate Therapeutics today. The company’s shares closed last Thursday at $1.49, close to its 52-week low of $0.83.
According to TipRanks.com, Bancroft is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fate Therapeutics with a $4.75 average price target.
